---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-22-013566"
form_type: "8-K"
ticker: "TENX"
cik: "0000034956"
company_name: "TENAX THERAPEUTICS, INC."
filed_at: "2022-10-11T23:59:59+00:00"
generated_at: "2026-06-23T04:33:46.327261+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Tenax Therapeutics announces positive oral levosimendan data in PH-HFpEF patients at HFSA meeting

## Summary
- 18 PH-HFpEF patients transitioned from IV to oral levosimendan with no serious adverse events reported.
- 6-minute walk distance improved by mean 13.1 m; BNP decreased by mean 133.3 pg/dL; NT-proBNP decreased by 239.4 pg/dL.
- KCCQ overall summary score improved 3.7 points; physical and clinical summary scores also improved.
- Oral formulation at 3-4 mg/day deemed safe and effective for chronic use, supporting Phase 3 testing.
- Data presented at HFSA Scientific Sessions 2022; investigators concluded oral levosimendan is well tolerated.

## SEC filing metadata
- accession: 0001654954-22-013566
- form_type: 8-K
- ticker: TENX
- cik: 0000034956
- company_name: TENAX THERAPEUTICS, INC.
- filed_at: 2022-10-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/34956/000165495422013566/0001654954-22-013566-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/34956/000165495422013566/tenx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-22-013566
- JSON: https://secwatch.observer/filing/0001654954-22-013566.json
- Plain text: https://secwatch.observer/filing/0001654954-22-013566.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.